Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

CIBA-GEIGY WILL CONTRIBUTE $20 MIL. TO ARTHRITIS RESEARCH at the University of California, San Diego School of Medicine, UCSD and Ciba-Geigy said in a March 6 joint announcement. The agreement establishes a new arthritis research unit at the UCSD School of Medicine. The program will be affiliated with the University of California's Institute for Research on Aging, an eight-year-old research unit that share the UCSD medical school facilities. Ciba-Geigy will have to option to obtain exclusive worldwide licenses for applications of the research it funds through the program. The firm's Voltaren (diclofenac sodium) is the largest-selling nonsteroidal anti-inflammatory treatment for arthritis symptoms. Launched a year-and-a-half ago, Voltaren has already surpassed $100 mil. in U.S. sales. The program will be headed by rheumatologist Dennis Carson, MD. The participation of Carson, who is being recruited from the Scripps Clinic, was central to Ciba-Geigy's interest in the program, according to the university. Carson has been affiliated with Scripps Clinic since 1976 and has served as division head of clinical immunology since 1986. He is scheduled to join the UCSD School on Medicine in June as professor of medicine and member of the Institute for Research on Aging. Under the agreement, Ciba-Geigy will give approximately $1 mil. a year in direct support of research done by Carson and his staff over the next six years. The support will be renewable for an additional four years. Ciba will also donate $6.6 mil. toward construction of a new clinical science facility being built on the UCSD campus, with additional funds for the lease of interim space for the arthritis researchers. The program will have a dual focus on research of rheumatoid arthritis and osteoarthritis and will seek to identify new therapies for both conditions. Osteoarthritis research will additionally focus on isolating the factors that cause degeneration of connective tissue in the disease. The program's rheumatoid arthritis research effort will concentrate on improved tests to assess and monitor the disease, advancement of methods of evaluating new drugs prior to administration to patients, and definition of the disease's underlying causes.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts